|
In order to view this program you must log in. If you do not have an account, please register for one.
Viewing the webcast requires use of the free RealPlayer. 
If you are having problems viewing the program, please check out our technical support section.
|
| Credits | 1.00 |
| Release Date | 11/6/2009 |
| Termination Date | 11/6/2012 |
| Cost |
$25.00 to view the program and complete a post test for CME credit. To purchase this program please log in.
|
| Description | The American Urological Association foundation states that with timely diagnosis and treatment, kidney cancer can be cured. If found early, the survival rate for patients with kidney cancer ranges from 79 to 100 percent.
|
| Accreditation Statement | The Ohio State University Medical Center, Center for Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The Ohio State University Medical Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| Author | Ahmad Shabsigh, MD and David Sharp, MD |
| Objectives | Upon completion of this educational activity, the participant should be able to: 1.) Explain the incidence and etiology of renal cell carcinoma. 2.) Review the systemic approach in diagnosing and staging renal cell carcinoma. 3.) Discuss current surgical management of small renal masses. 4.) Describe how new targeted therapies are the standard of care for metastatic renal cancer.
|
| Audience | This course is designed for physicians. |
| Estimated Time to Complete | 1 Hour |
